Advertisement

Neurobiochemie der Neuroleptika

  • W. E. Müller
Conference paper
Part of the Tropon-Symposium book series (BAYERZNS, volume 2)

Zusammenfassung

Seit den ersten Berichten über die relativ spezifische antipsychotische Wirksamkeit des Chlorpromazins (Delay u. Deniker 1952) und des Reserpins (Kline 1954), hat sich die experimentelle Pharmakologie sehr intensiv bemüht, den Mechanismus der antipsychotischen Wirkung beider Substanzen und der vielen von ihnen abgeleiteten Verbindungen aufzuklären. Dies hat im wesentlichen zwei Gründe: Zum einen ist eine genaue Kenntnis des Wirkungsmechanismus eines Pharmakons immer noch eine der wesentlichen Grundlagen einer rationalen Pharmakotherapie. Zum anderen war die Suche nach dem Wirkungsmechanismus der Antipsychotika immer von der Hoffnung getragen, über den Wirkungsmechanismus einen Schlüssel zum Verständnis der biologischen Ursachen der Schizophrenie in die Hand zu bekommen (Carlsson 1978).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ackenheil M, Albus M, Bondy B, Müller-Spahn F, Winch U, Naber D (1985) Biochemical and neuroendocrine studies in schizophrenia: attemps to characterize the illness biochemically. In: Beckmann H, Riederer P (eds) Pathochemical markers in major psychoses. Springer, Berlin Heidelberg New York Tokyo, pp 78–87CrossRefGoogle Scholar
  2. Angrist B, Kaminen DP van (1984) CNS stimulants as tools in the study of schizophrenia. TINS 7: 388–390Google Scholar
  3. Benkert O, Hippius H (1986) Psychiatrische Pharmakotherapie, 4. Aufl. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  4. Birkmayer W, Riederer P (1980) Die Parkinson-Krankheit Biochemie, Klinik, Therapie. Springer, Wien New YorkGoogle Scholar
  5. Bischoff S, Delini-Stula A, Maitre L (1985) Blockade der Dopamin-Rezeptoren im Hippokampus als Indikator antipsychotischer Wirksamkeit: Korrelationen zwischen neurochemischen und psychopharmakologischen Wirkungen von Neuroleptika. In: Pflug B, Foerster K, Straube E (Hrsg) Perspektiven der Schizophrenie-Forschung. Fischer, Stuttgart, S 87–103Google Scholar
  6. Bürki HR (1986) Effects of fluperlapin on dopaminergic systems in rat brain. Psychopharmacology 89: 77–84PubMedCrossRefGoogle Scholar
  7. Carlsson A (1978) Does dopamine have a role in schizophrenia? Biol Psychiatry 13: 3–21PubMedGoogle Scholar
  8. Chiodo LA, Bunney BS (1985) Possible mechanisms by which repeated clozapine administration differently affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 5: 2539–2544PubMedGoogle Scholar
  9. Crow TJ (1982) Schizophrenia. In: Crow TJ (ed) Disorders of neurohumoral transmission. Academic Press, London, pp 287–340Google Scholar
  10. Crow TJ, Taylor GR, Tyrell DAJ (1986) Two syndromes in schizophrenia and the viral hypothesis. In: Burrows GD, Norman TR, Rubinstein G (eds) Handbook of studies on schizophrenia, Part 1: Epidemiology, aetiology and clinical features. Elsevier, Amsterdam, pp 83–96Google Scholar
  11. Davis JM (1965) Efficacy of tranquilizing and antidepressant drugs. Arch Gen Psychiatry 13: 552–572PubMedCrossRefGoogle Scholar
  12. De Graaf JS, Pinder RM (1986) Antipsychotics of the future. In: Burrows GD, Norman TR, Rubinstein G (eds) Handbook of studies on schizophrenia, Part 2: Management and research. Elsevier, Amsterdam, pp 47–66Google Scholar
  13. Delay J, Deniker P (1952) Cas de psychoses traités par la cure prolongée et continué de 4568 RP. Ann Med Psychol 110: 364Google Scholar
  14. Delini-Stula A (1986) Neuroanatomical, neuropharmacological and neurobiochemical target systems for antipsychotic activity of neuroleptics. Pharmacopsychiatrie 19: 134–139CrossRefGoogle Scholar
  15. DeLisi LE (1986) The third biannual winter workshop on schizophrenia. Arch Gen Psychiatry 43: 706–711PubMedCrossRefGoogle Scholar
  16. Ellison GD, Eison MS (1983) Continuous amphetamine intoxication: an animal model of the acute psychotic episode. Psychol Med 13: 751–761PubMedCrossRefGoogle Scholar
  17. Giannini AJ, Loiselle RH, Price WA, Giannini MC (1985) Chlorpromazine vs. meperidine in the treatment of phencyclidine. J Clin Psychiatry 46: 52–54PubMedGoogle Scholar
  18. Goodwin GM, Metz A (1985) Neuroleptics. In: Grahame-Smith DG (ed) Psychopharmacology 2, Part 1: Preclinical psychopharmacology. Elsevier, Amsterdam, pp 206–238Google Scholar
  19. Greenberg BD, Segal DS, Jacobs BL (1985) Hallucinogens: Phencyclidine. In: Grahame-Smith DG (ed) Psychopharmacology 2, Part 1: Preclinical psychopharmacology. Elsevier, Amsterdam, pp 343–363Google Scholar
  20. Gruzelier JH (1986) Theories of lateralised and interhemispheric dysfunction in syndromes of schizophrenia. In: Burrows GD, Norman TR, Rubinstein G (eds) Handbook of studies on schizophrenia, Part 2: Management and research. Elsevier, Amsterdam, pp 175–187Google Scholar
  21. Härnryd C, Bjerkenstedt L, Björk K (1984 a) Clinical evaluation of sulpiride in schizophrenic patients — A double-blind comparison with chlorpromazine. Acta Psychiatr Scand 69 [Suppl 311]:7–30Google Scholar
  22. Härnryd C, Bjerkenstedt L, Gullberg B (1984b) Time course for the effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Acta Psychiatr Scand 69 [Suppl] 3111:75–92CrossRefGoogle Scholar
  23. Jenner P, Marsden CD (1983) Neuroleptics. In: Grahame-Smith DG (ed) Psychopharmacology 1, Part 1: Preclinical psychopharmacology. Elsevier, Amsterdam, pp 180–247Google Scholar
  24. Kline NS (1954) Use of rauwolfia serpentina benth in neuropsychiatric conditions. Ann NY Acad Sci 59: 107–117PubMedCrossRefGoogle Scholar
  25. Lindström L, Besev G, Stening G, Widerlöv E (1985) An open study of remoxipride, a benzamide derivative, in schizophrenia. Psychopharmacology 86: 241–243PubMedCrossRefGoogle Scholar
  26. Lund-Laursen A, Gerlach J (1986) Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity. Acta Psychiatr Scand 73: 17–21PubMedCrossRefGoogle Scholar
  27. Magnusson O, Fowler CJ, Köhler C, Ogren SO (1986) Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs. Neuropharmacology 25: 187–197Google Scholar
  28. McCreadie RG, Morrison D, Eccleston D, Gall RG, Loudon J, Mitchell MJ (1985) An open multicentre study of the treatment of florid schizophrenia with remoxipride. Acta Psychiatr Scand 72: 139–143PubMedCrossRefGoogle Scholar
  29. Nordberg A, Nyberg P, Windblad B (1985) Topographic distribution of choline acetyltransferase activity and muscarinic and nicotinic receptors in Parkinson brains. Neurochem Pathol 3: 223–236PubMedGoogle Scholar
  30. Ogren SO, Hall H, Köhler C, Magnusson O, Lindbom LO, Ängeby K, Florvall L (1984) Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 102: 459–474PubMedCrossRefGoogle Scholar
  31. Ortiz A, Gershon S (1986) The future of neuroleptic psychopharmacology. J Clin Psychiatry 47 [Suppl 5]: 3–11PubMedGoogle Scholar
  32. Pearlson GD (1981) Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. Johns Hopkins Med J 148: 25–33PubMedGoogle Scholar
  33. Reisine TD, Fields JZ, Yamamura HI, Bird ED, Spokes E, Schreiner PS, Enna SJ (1977) Neurotransmitter receptor alterations in Parkinson’s disease. Life Sci 21: 335–344PubMedCrossRefGoogle Scholar
  34. Reynolds GP (1983) Increased concentrations and lateral asymmetry of amygdale dopamine in schizophrenia. Nature 305: 527–529PubMedCrossRefGoogle Scholar
  35. Riederer P, Reynolds GP (1985) Brain biochemistry in schizophrenia an assessment. In: Beckmann H, Riederer P (eds) Pathochemical markers in major psychoses. Springer, Berlin Heidelberg New York Tokyo, pp 35–43CrossRefGoogle Scholar
  36. Roth RH, Bacopoulos NG, Bustos G, Redmond DE (1980) Antipsychotic drugs: differential effects on dopamine neurons in basal ganglia and mesocortex following chronic administration in human and nonhuman primates. In: Cattabeni F, Racagni G, Spano PF, Costa E (eds) Long-term effects of neuroleptics. Raven Press, New York, pp 513–520Google Scholar
  37. Rüther E (1986) Wirkungsverlauf der neuroleptischen Therapie. Fischer, StuttgartGoogle Scholar
  38. Sedvall G, Farde L, Persson A, Wiesel FA (1986) Imaging of neurotransmitter receptors in the living human brain. Arch Gen Psychiatry 43: 995–1005PubMedCrossRefGoogle Scholar
  39. Seeman P (1986) Dopamine/neuroleptic receptors in schizophrenia. In: Burrows GD, Norman TR, Rubinstein G (eds) Handbook of studies on schizophrenia, Part 2: Management and research. Elsevier, Amsterdam, pp 243–251Google Scholar
  40. Snyder SH (1982) Neurotransmitters and CNS disease: Schizophrenia. Lancet 11: 970–974CrossRefGoogle Scholar
  41. Snyder SH, Greenberg D, Yamamura HI (1974) Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 31: 58–61PubMedCrossRefGoogle Scholar
  42. StoofJC, Kebabian JW (1984) Two dopamine receptors: Biochemistry, physiology, and pharmacology. Life Sci 35: 2281–2296Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • W. E. Müller

There are no affiliations available

Personalised recommendations